Literature DB >> 3190188

In vitro activity of carumonam (Ro 17-2301; AMA-1080) versus enteropathogenic and nonfermentative gram-negative rods and Legionella pneumophila.

P Hohl1, A von Graevenitz, J Zollinger-Iten.   

Abstract

The in vitro activity of carumonam (Ro 17-2301; AMA-1080) was tested against 355 single-patient isolates, by and large enteropathogenic or nonfermentative rods. The new monobactam was inhibitory and bactericidal against the majority of diarrhea-causing members of the family Enterobacteriaceae at concentrations of less than and equal to 8 micrograms/ml. Although known to be active against Pseudomonas aeruginosa, it generally did not exhibit clinically useful activity against other nonfermenters or against Legionella pneumophila, thus confirming its narrow spectrum of activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190188      PMCID: PMC175927          DOI: 10.1128/AAC.32.10.1593

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Susceptibility testing of carumonam: interpretive criteria for 30-microgram disk tests and quality control guidelines for disk diffusion and broth microdilution methods.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

2.  In-vitro antibacterial activity of AMA-1080.

Authors:  K Matsuda; Y Hamana; M Inoue; S Mitsuhashi
Journal:  J Antimicrob Chemother       Date:  1985-11       Impact factor: 5.790

3.  In vitro activity of carumonam.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

4.  In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.

Authors:  P C Fuchs; R N Jones; A L Barry; L W Ayers; T L Gavan; E H Gerlach
Journal:  Diagn Microbiol Infect Dis       Date:  1986-11       Impact factor: 2.803

5.  The in-vitro activity and beta-lactamase stability of carumonam.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

6.  Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli.

Authors:  W L Wang; L B Reller; M J Blaser
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

7.  Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli.

Authors:  D A Strandberg; J H Jorgensen; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic.

Authors:  A Imada; M Kondo; K Okonogi; K Yukishige; M Kuno
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

9.  The in-vitro activity of Ro 17-2301, a new monobactam, compared with other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Piddock
Journal:  J Antimicrob Chemother       Date:  1985-02       Impact factor: 5.790

10.  Susceptibility of Legionella pneumophila to twenty antimicrobial agents.

Authors:  P H Edelstein; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

  10 in total
  1 in total

1.  Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; W Ritz
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.